Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases

Annals of Surgery

Volumn 267, Issue 3, 2018, Pages 514-520

  Yamashita, Suguru ^a   Brudvik, Kristoffer Watten ^a   Kopetz, Scott E ^a   Maru, Dipen ^a   Clarke, Callisia N ^a   Passot, Guillaume ^a   Conrad, Claudius ^a   Chun, Yun Shin ^a   Aloia, Thomas A ^a   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

colon cancer liver metastases (CCLM); colorectal liver metastases (CLM); embryonic; origin

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RAS PROTEIN; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; COLON SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDGUT; MUTANT; MUTATION; OVERALL SURVIVAL; PREDICTOR VARIABLE; PREOPERATIVE CHEMOTHERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; CANCER STAGING; COLORECTAL TUMOR; EMBRYOLOGY; GENETICS; LIVER TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SECONDARY; SURVIVAL RATE;

AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE;

EID: 85007198120     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002087     Document Type: Article

References (27)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
2. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
3. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825.
4. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988-993.
5. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847-854.
6. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113:779-788.
7. Hutchins G, Southward K, Handley K, et al. KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer, value of mismatch repair. J Clin Oncol. 2011;29:1261-1270.
8. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101:403-408.
9. Price TJ, Beeke C, Ullah S, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer. 2015;121:830-835.
10. Pugh SA, Shinkins B, Fuller A, et al. Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACS randomized controlled trial. Ann Surg. 2016;263:1143-1147.
11. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107:3.
12. Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344-5351.
13. Mise Y, Zimmitti G, Shindoh J, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22:834-842.
14. Brudvik KW, Kopetz SE, Li L, et al. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102:1175-1183.
15. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-1123.
16. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectalmetastases. Ann Surg. 2005;241:715-722.
17. Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009;250:540-548.
18. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338-2344.
19. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619-626.
20. Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29:1083-1090.
21. Andreou A, Aloia TA, Brouquet A, et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg. 2013;257:1079-1088.
22. Boisen MK, Johansen JS, Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol. 2013;24:2554-2559.
23. Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33: 4032-4038.
24. Shiovitz S, Bertagnolli MM, Renfro LA, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014;147:637-645.
25. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005;11:6212-6217.
26. Messick CA, Sanchez J, Dejulius KL, et al. Genetic and molecular diversity of colon cancer hepatic metastases. Surgery. 2009;146:227-231.
27. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104:1020-1026.